IDEX BIOMETRICS ASA
Reference is made to the private placement of about 83.2 million shares in IDEX Biometrics ASA on 15 February 2021. The capital increase has been registered. The company’s share capital is now NOK 137,304,213.30 divided into 915,361,422 shares, each with a par value of NOK 0.15.
A listing prospectus will be prepared and published as soon as practical. About 29.4 million of the new shares have been issued to a separate, temporary ISIN and that will be restricted from trading on Oslo Børs until after publication of the prospectus.
For further information contact:
Marianne Bøe, Investor Relations
E-mail: marianne.boe@idexbiometrics.com
Tel: + 47 9180 0186
Derek D’Antilio, Chief Financial Officer
E-mail: derek.dantilio@idexbiometrics.com
Tel: +1 978 273 1344
About IDEX Biometrics
IDEX Biometrics ASA (OSE: IDEX and OTCQB: IDXAF) is a leading provider of fingerprint identification technologies offering simple, secure and personal touch-free authentication for all. We help people make payments, prove their identity, gain access to information, unlock devices or gain admittance to buildings. We invent, engineer, and commercialize these secure and safe yet incredibly user-friendly solutions. Our total addressable market represents a fast growing multi-billion-unit opportunity.
For more information, visit www.idexbiometrics.com and follow @IDEXBiometrics.
This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Aduro Clean Technologies Inc.23.10.2025 13:00:00 CEST | Press release
Aduro Clean Technologies Advances Demonstration Plant Program with Extruder Engineering Trials
Amphista Therapeutics23.10.2025 13:00:00 CEST | Press release
Amphista Therapeutics announces three key strategic leadership appointments to drive transition of its Targeted Glue™ protein degraders into clinical development
George Medicines23.10.2025 13:00:00 CEST | Press release
TRIDENT, a dedicated stroke outcomes trial in patients with a history of intracerebral hemorrhage (ICH), demonstrates the potential advantages of intensive blood pressure treatment with low-dose triple combination therapyTRIDENT, a dedicate
Nykredit Realkredit A/S23.10.2025 12:27:51 CEST | Pressemeddelelse
Fastsættelse af kuponrenter - Nykredit Realkredit A/S
Nykredit Realkredit A/S23.10.2025 12:27:51 CEST | Press release
Fixing of coupon rates - Nykredit Realkredit A/S
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom